Parameter Set Antiarrhythmic Drugs - LC-MS/MS

Order No.: 92923
Parameters:
Acebutolol, Ajmaline, Amiodarone, Aprindine, Atenolol, Bisoprolol, Debutyldronedarone, Desethylamiodarone, Diltiazem, Disopyramide, Dronedarone, Flecainide, Flunarizine, Gallopamil, Hydroquinidine, Lidocaine, Metoprolol, Mexiletine, Norverapamil, Propafenone, Propranolol, Quinidine, Sotalol, Tocainide, Verapamil

Encompasses 25 analytes
3PLUS1® Multilevel Calibrator Set available
Part of the MassTox® TDM Series A

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR 2017/746

Acebutolol

Ajmaline

Amiodarone

Desethylamiodarone

Aprindine

Atenolol

Bisoprolol

Diltiazem

Disopyramide

Dronedarone

Debutyldronedarone

Flecainide

Flunarizine

Gallopamil

Lidocaine

Metoprolol

Mexiletine

Propafenone

Propranolol

Quinidine

Hydroquinidine

Sotalol

Tocainide

Verapamil

Norverapamil

Clinical relevance

Antiarrhythmic drugs are used for the treatment of cardiac arrhythmia to reduce their frequency or intensity. The severity of ventricular and supraventricular rhythm disturbances ranges from harmless extra beats through to complex multiple blows and life-threatening tachycardia. By using antiarrhythmic agents, it is possible to restore a normal electrical cardiac activity. Since antiarrhythmic drugs are an inhomogeneous group, in their chemistry and mechanisms of action, various side effects and drug interactions have to be considered. Their use should be monitored by ECG monitoring, electrolyte and plasma level determinations, in particular when starting new drug regimens. As each antiarrhythmic drug possesses a pro-arrhythmic potential, it also can cause cardiac arrhythmia. Furthermore, there are drug-drug interactions between the different antiarrhythmics, and therefore, combinations should be taken with extreme caution as well as with due attention to the side-effects and interaction profiles. For these reasons cardiac arrhythmia are often only treated with medication when they are very dangerous or associated with a high burden for the patient.

 

Product advantages

With the Parameter Set Antiarrhythmic Drugs in serum/plasma, 25 different drugs can be measured quickly and efficiently using LC-MS/MS. By carefully optimising all of the kit components and the chromatographic separation, matrix effects (“ion suppression”) have been minimised and the robustness of the method has been enhanced. Sample preparation is based on protein precipitation. The use of stable isotopically labelled (deuterated), co-eluting internal standards as well as the 3PLUS1® multilevel calibrator guarantees high precision and reliable quantification. The method is comprehensively validated.

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory. The Basic Kit A contains all components required for sample preparation and all necessary mobile phases. The MasterColumn® A is the analytical column used for the determination of all Series A analytes. Our portfolio contains further MassTox® Parameter Sets.

For the analysis you require the MassTox® TDM Basic Kit A, the specific MassTox® TDM Parameter Set and the analytical column MassTox® TDM MasterColumn® A.

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 1.5 – 80 µg/l
Upper Limit of Quantification up to 30000 µg/l
Recovery 87 – 109 %
Intraassay CV = 2 – 9 %
Interassay CV = 3 – 8.5 %
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix
  • Add 800 µl Internal Standard Mix to 12 ml Precipitation Reagent (= mixture A).
  • Pipette 50 µl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial.
  • Add 25 µl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 µl of mixture A, mix 30 s (vortex) and centrifuge 5 min.
  • Dilute supernatant with Dilution Buffer (depending on instrument sensitivity) and inject into LC-MS/MS system.
Run Time 1.2 – 3.5 min
Injection Volume 0.2 – 50 µl
Gradient

Group 1
isocratic 25 % Mobile Phase 2
Group 2
isocratic 43 % Mobile Phase 2
Group 3
isocratic 65 % Mobile Phase 2
Group 4
0.00–0.40 min      0 % Mobile Phase 2
0.41–1.00 min    80 % Mobile Phase 2
1.01–2.90 min  100 % Mobile Phase 2
2.91–3.50 min       0 % Mobile Phase 2

Ionisation ESI positive
MS/MS Mode MRM
Parameters Acebutolol, Ajmaline, Amiodarone, Aprindine, Atenolol, Bisoprolol, Debutyldronedarone, Desethylamiodarone, Diltiazem, Disopyramide, Dronedarone, Flecainide, Flunarizine, Gallopamil, Hydroquinidine, Lidocaine, Metoprolol, Mexiletine, Norverapamil, Propafenone, Propranolol, Quinidine, Sotalol, Tocainide, Verapamil
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
General lab equipment (non-CE-IVD products), available from Chromsystems:
As a customer please login or register to gain full access.

Acebutolol

Ajmaline

Amiodarone

Desethylamiodarone

Aprindine

Atenolol

Bisoprolol

Diltiazem

Disopyramide

Dronedarone

Debutyldronedarone

Flecainide

Flunarizine

Gallopamil

Lidocaine

Metoprolol

Mexiletine

Propafenone

Propranolol

Quinidine

Hydroquinidine

Sotalol

Tocainide

Verapamil

Norverapamil

Clinical relevance

Antiarrhythmic drugs are used for the treatment of cardiac arrhythmia to reduce their frequency or intensity. The severity of ventricular and supraventricular rhythm disturbances ranges from harmless extra beats through to complex multiple blows and life-threatening tachycardia. By using antiarrhythmic agents, it is possible to restore a normal electrical cardiac activity. Since antiarrhythmic drugs are an inhomogeneous group, in their chemistry and mechanisms of action, various side effects and drug interactions have to be considered. Their use should be monitored by ECG monitoring, electrolyte and plasma level determinations, in particular when starting new drug regimens. As each antiarrhythmic drug possesses a pro-arrhythmic potential, it also can cause cardiac arrhythmia. Furthermore, there are drug-drug interactions between the different antiarrhythmics, and therefore, combinations should be taken with extreme caution as well as with due attention to the side-effects and interaction profiles. For these reasons cardiac arrhythmia are often only treated with medication when they are very dangerous or associated with a high burden for the patient.

 

Product advantages

With the Parameter Set Antiarrhythmic Drugs in serum/plasma, 25 different drugs can be measured quickly and efficiently using LC-MS/MS. By carefully optimising all of the kit components and the chromatographic separation, matrix effects (“ion suppression”) have been minimised and the robustness of the method has been enhanced. Sample preparation is based on protein precipitation. The use of stable isotopically labelled (deuterated), co-eluting internal standards as well as the 3PLUS1® multilevel calibrator guarantees high precision and reliable quantification. The method is comprehensively validated.

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory. The Basic Kit A contains all components required for sample preparation and all necessary mobile phases. The MasterColumn® A is the analytical column used for the determination of all Series A analytes. Our portfolio contains further MassTox® Parameter Sets.

For the analysis you require the MassTox® TDM Basic Kit A, the specific MassTox® TDM Parameter Set and the analytical column MassTox® TDM MasterColumn® A.

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 1.5 – 80 µg/l
Upper Limit of Quantification up to 30000 µg/l
Recovery 87 – 109 %
Intraassay CV = 2 – 9 %
Interassay CV = 3 – 8.5 %
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix
  • Add 800 µl Internal Standard Mix to 12 ml Precipitation Reagent (= mixture A).
  • Pipette 50 µl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial.
  • Add 25 µl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 µl of mixture A, mix 30 s (vortex) and centrifuge 5 min.
  • Dilute supernatant with Dilution Buffer (depending on instrument sensitivity) and inject into LC-MS/MS system.
Run Time 1.2 – 3.5 min
Injection Volume 0.2 – 50 µl
Gradient

Group 1
isocratic 25 % Mobile Phase 2
Group 2
isocratic 43 % Mobile Phase 2
Group 3
isocratic 65 % Mobile Phase 2
Group 4
0.00–0.40 min      0 % Mobile Phase 2
0.41–1.00 min    80 % Mobile Phase 2
1.01–2.90 min  100 % Mobile Phase 2
2.91–3.50 min       0 % Mobile Phase 2

Ionisation ESI positive
MS/MS Mode MRM
Parameters Acebutolol, Ajmaline, Amiodarone, Aprindine, Atenolol, Bisoprolol, Debutyldronedarone, Desethylamiodarone, Diltiazem, Disopyramide, Dronedarone, Flecainide, Flunarizine, Gallopamil, Hydroquinidine, Lidocaine, Metoprolol, Mexiletine, Norverapamil, Propafenone, Propranolol, Quinidine, Sotalol, Tocainide, Verapamil
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
General lab equipment (non-CE-IVD products), available from Chromsystems:
As a customer please login or register to gain full access.